MX2020011377A - Metodos y composiciones para el tratamiento de urticaria cronica. - Google Patents

Metodos y composiciones para el tratamiento de urticaria cronica.

Info

Publication number
MX2020011377A
MX2020011377A MX2020011377A MX2020011377A MX2020011377A MX 2020011377 A MX2020011377 A MX 2020011377A MX 2020011377 A MX2020011377 A MX 2020011377A MX 2020011377 A MX2020011377 A MX 2020011377A MX 2020011377 A MX2020011377 A MX 2020011377A
Authority
MX
Mexico
Prior art keywords
treatment
chronic urticaria
compositions
methods
antibodies
Prior art date
Application number
MX2020011377A
Other languages
English (en)
Spanish (es)
Inventor
Nenad Tomasevic
Christopher Robert Bebbington
Henrik Rasmussen
Original Assignee
Allakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allakos Inc filed Critical Allakos Inc
Publication of MX2020011377A publication Critical patent/MX2020011377A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2020011377A 2018-05-04 2019-05-03 Metodos y composiciones para el tratamiento de urticaria cronica. MX2020011377A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862667242P 2018-05-04 2018-05-04
US201962788719P 2019-01-04 2019-01-04
US201962797817P 2019-01-28 2019-01-28
US201962803211P 2019-02-08 2019-02-08
US201962806657P 2019-02-15 2019-02-15
PCT/US2019/030523 WO2019213468A1 (en) 2018-05-04 2019-05-03 Methods and compositions for treating chronic urticaria

Publications (1)

Publication Number Publication Date
MX2020011377A true MX2020011377A (es) 2020-11-24

Family

ID=68386174

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011377A MX2020011377A (es) 2018-05-04 2019-05-03 Metodos y composiciones para el tratamiento de urticaria cronica.

Country Status (11)

Country Link
US (1) US20210246205A1 (cg-RX-API-DMAC7.html)
EP (1) EP3788078A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021523117A (cg-RX-API-DMAC7.html)
KR (1) KR20210005245A (cg-RX-API-DMAC7.html)
CN (1) CN112384535A (cg-RX-API-DMAC7.html)
AU (1) AU2019262167A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020022236A2 (cg-RX-API-DMAC7.html)
CA (1) CA3099338A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020011377A (cg-RX-API-DMAC7.html)
SG (1) SG11202010911WA (cg-RX-API-DMAC7.html)
WO (1) WO2019213468A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019022912A2 (pt) 2017-05-05 2020-05-26 Allakos Inc. Métodos e composições para tratar doenças oculares alérgicas
EP4180454A4 (en) * 2020-07-10 2024-10-02 Shanghai Jemincare Pharmaceuticals Co., Ltd. Anti-ige engineered antibody and application thereof
KR102803012B1 (ko) * 2022-08-11 2025-04-30 오씨아이 주식회사 석유계 고연화점 피치의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6715767B2 (ja) * 2013-10-23 2020-07-01 ジェネンテック, インコーポレイテッド 好酸球性疾患の診断及び治療方法
KR20210125114A (ko) * 2013-12-09 2021-10-15 알라코스 인크. 항-Siglec-8 항체 및 그의 사용 방법
JP6825909B2 (ja) * 2014-02-28 2021-02-03 アラコス インコーポレイテッド シグレック−8関連疾患を処置するための方法および組成物
US10604577B2 (en) * 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis

Also Published As

Publication number Publication date
AU2019262167A1 (en) 2020-12-10
JP2024045612A (ja) 2024-04-02
JP2021523117A (ja) 2021-09-02
EP3788078A4 (en) 2022-03-02
BR112020022236A2 (pt) 2021-02-02
CA3099338A1 (en) 2019-11-07
SG11202010911WA (en) 2020-12-30
CN112384535A (zh) 2021-02-19
US20210246205A1 (en) 2021-08-12
KR20210005245A (ko) 2021-01-13
WO2019213468A1 (en) 2019-11-07
EP3788078A1 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
CO2021003036A2 (es) Compuestos de anillo fusionado
CL2021000039A1 (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas (divisional solicitud 201903796)
CO2021005987A2 (es) Compuestos de anillo fusionado
CO2019001212A2 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos
CL2018002878A1 (es) Composiciones y anticuerpos anti-tim-3.
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
CL2019000508A1 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados.
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
CO2019013669A2 (es) Anticuerpos anti-garp-tgf-β
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
PE20161390A1 (es) Anticuerpos multiespecificos
MX2016014253A (es) Inhibidores de desmetilasa-1 especifica de lisina.
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2018010993A (es) Derivados de icariina e icaritina.
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.